The article from the Africa Centres for Disease Control and Prevention (Africa CDC) website, titled “PAHO and Africa CDC strengthen collaboration to address access to essential medicines and vaccines,” emphasises a vital partnership aimed at improving access to essential medicines and vaccines. This collaboration signifies a commitment to enhance health outcomes in both Africa and the Americas.
On September 20, 2024, Pan American Health Organization (PAHO) and Africa CDC agreed to collaborate on equitable access to vaccines and health technologies during Africa CDC’s first official visit to PAHO in Washington, D.C.
The partnership prioritises equitable access by enhancing regional regulatory, innovation, and production mechanisms to improve access to essential medicines and vaccines in Africa and the Americas. Furthermore, it aims to enhance regional manufacturing capacities through initiatives like the African Pooled Procurement Mechanism (APPM) and the Partnerships for African Vaccine Manufacturing (PAVM). PAVM aims to empower African vaccine manufacturing to provide over 60% of the continent’s vaccine needs by 2040.
– Pooled Procurement Mechanism: PAHO will share its expertise on operationalising regional revolving funds. Therefore, supporting Africa CDC in implementing the APPM. This mechanism is intended to improve access to quality and affordable health products and promote local manufacturing.
– Regulatory and Production Strategies: The discussions focused on demand consolidation, planning, quality, and logistics. Further also strengthening regulatory and regional production strategies to improve access to essential medicines.
– Research and Innovation: Advancing research, innovation, and digital transformation of health systems to effectively address public health challenges.
– Emergency Response: The collaboration will build resilience by improving preparedness and response to health emergencies, including the ongoing Mpox outbreak. Africa CDC briefed PAHO on the Mpox continental response plan, which emphasises access to lifesaving vaccines.
Dr. Jarbas Barbosa, PAHO Director, highlighted the objective of cultivating a more resilient region by enhancing regional manufacturing capabilities. Therefore, ultimately decreasing reliance on global interventions during crucial emergencies. On the other hand, Dr. Jean Kaseya, Africa CDC Director General, emphasised the significance of this partnership in advancing health outcomes through collaborative efforts.
The collaboration seeks to promote broader strategic priorities in both regions, with a focus on improving and safeguarding health. This includes exploring opportunities for south-south cooperation that can address health challenges and capitalize on the strengths of both regions.
In conclusion,this partnership aims to enhance health outcomes, access to essential products, and strengthen health systems in Africa and the Americas. The commitment to addressing access to essential medicines and vaccines reflects a strategic approach to global health collaboration.
💊 International drug price comparison reveal stark price gaps—the U.S. pays 4.2 times more for brand-name drugs than OECD peers.
But are these studies fueling a market collapse or opening a strategic opportunity for sustainable pricing in the U.S. and globally?
Discover the shortcomings of international pricing comparisons and how robust drug pricing analysis can help balance access, affordability, and profitability in a complex market.
#SyenzaNews #healthcare #pricing
🌐 Are you ready to witness a paradigm shift in digital health technology?
The National Institute for Health and Care Excellence (NICE) has announced transformative reforms aimed at accelerating the adoption of digital health innovations within the NHS. By focusing on cost-effectiveness rather than mere cost savings, these changes promise to streamline regulatory processes and enhance evaluations aligned with healthcare priorities.
Dive into this insightful article to explore how NICE’s reforms could reshape the future of healthcare systems globally!
#SyenzaNews #DigitalHealth #HealthEconomics #Innovation
🚀 What could a groundbreaking partnership between BioNTech and Bristol-Myers Squibb mean for the future of solid tumor therapy?
Their collaboration on BNT327 is set to revolutionize immuno-oncology with promising early-phase trial results and a strategic investment of over $1.5 billion. This innovative bispecific antibody targets both PD-L1 and VEGF-A, indicating potential for enhanced patient outcomes in challenging cancers like small cell lung cancer and triple-negative breast cancer.
Curious about how this partnership could reshape cancer treatments? Dive into the full analysis!
#SyenzaNews #oncology #drugdevelopment #MarketAccess
SPEAK WITH US
CORRESPONDENCE ADDRESS
1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA
WRITE US
JOIN NEWSLETTER
